Blood transfusion · newly diagnosed patients with myelodysplastic syndromes
1 finding from 1 review
Mortality (12 months · newly diagnosed patients with myelodysplastic syndromes
GM‐CSF showed no clear difference in mortality (12 months compared with placebo (low certainty).
1 finding from 1 review
Progression‐free survival · newly diagnosed patients with myelodysplastic syndromes
1 finding from 1 review
Intervention not reported
Overall survival · people diagnosed with chemotherapy‐induced anemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Hematopoietic response · people diagnosed with chemotherapy‐induced anemia
The intervention leads to higher hematopoietic response (high certainty).
1 finding from 1 review
Intervention not reported
Red blood cell transfusion · people diagnosed with chemotherapy‐induced anemia
The intervention probably leads to lower red blood cell transfusion (moderate certainty).
1 finding from 1 review
Intervention not reported
Median time to hematopoietic response · people diagnosed with chemotherapy‐induced anemia
The intervention showed no clear difference in median time to hematopoietic response (low certainty).
1 finding from 1 review
Intervention not reported
Mean change in hemoglobin (better indicated by higher values) · people diagnosed with chemotherapy‐induced anemia
The intervention may leads to higher mean change in hemoglobin (better indicated by higher values) (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life (better indicated by higher values) · people diagnosed with chemotherapy‐induced anemia
The intervention showed no clear difference in quality of life (better indicated by higher values) (high certainty).
1 finding from 1 review
Intervention not reported
Thromboembolic events · people diagnosed with chemotherapy‐induced anemia
The intervention showed no clear difference in thromboembolic events (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality · people diagnosed with chemotherapy‐induced anemia
1 finding from 1 review
Number of participants with any bleeding · People with a haematological disorder
1 finding from 1 review
Thromboembolism · People with a haematological disorder
1 finding from 1 review
Mortality (all‐cause) ‐ not reported · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Adverse events associated with transfusion · People with a haematological disorder
1 finding from 1 review
Adverse events of antifibrinolytic agents · People with a haematological disorder
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
1 finding from 1 review
Overall survival · All patients with a diagnosis of multiple myeloma
Bortezomib leads to lower overall Survival compared with no bortezomib (high certainty).
1 finding from 1 review
Health‐related quality of life · All patients with a diagnosis of multiple myeloma
1 finding from 1 review